NOTION: TAVI with low risk at 4 year follow up

Courtesy of the SBHCI.

NOTION: TAVI with Low Risk at 4 Year Follow UpThere is little data about the use of transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis at low surgical risk. Many of the questions involve long term duration of valves (over 10 years) when treating younger patients with longer life expectancy.

 

The NOTION study aims at comparing TAVR (with the self-expandable CoreValve) vs. conventional valve replacement surgery in patients over 70 years old at low surgical risk. This article reports on its 4 year outcomes.

 

The NOTION (Nordic Aortic Valve Intervention) randomized 280 patients between 2009 and 2013 with a mean STS of around 3 (more than 80% had <4 STS).

 

Primary end point was a composite of death, infarction or stroke according to VARC II criteria, that resulted 30.2% at 4 year follow up for patients undergoing surgery vs. 29.1% for the TAVR group (p=0.76).

 

Global mortality was 23% for surgery vs. 20% for the TAVR group (p=0.56). Also the rate of stroke resulted similar (surgery 7.3% vs. TAVR 6.8%), as well as that of infarction.

 

When looking only at patients between 70 and 75 (all with STS ≤4), primary end point was 27.2% for surgery and 15.6% for TAVR (p=0.24).

 

The differences between methods were seen in atrial fibrillation, that was far more frequent in the surgery group (60.2% vs 24.5%; p<0.001), and in the need for pacemaker, far more frequent with TAVR (9% vs. 43.7%, p<0,001).

 

Conclusion

Patients with severe aortic stenosis at low risk randomized to surgery vs. transcatheter aortic valve replacement showed similar results at 4 years as regards primary end point.

 

Differences were seen basically in new atrial fibrillation rate, which favored TAVR and in the need of pacemaker, which favored surgery. 

 

Courtesy of SBHCI

 

Dr. Lars Sondergaard
Dr. Lars Sondergaard.

Original Title: Clinical, safety and echocardiographic outcomes from NOTION trial: 4-year follow-up data in all-comer patients with severe aortic valve stenosis.

Presenter: Lars Sondergaard.

 

 

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....